GSK Q1 beats estimates
GSK
1,775.00p
16:40 17/05/24
-0.48%
-8.50p
GSK first quarter profits and revenue both beat expectations driven by its shingles and meningitis treatments, among others.
FTSE 100
8,420.26
16:44 17/05/24
n/a
n/a
FTSE 350
4,631.57
16:49 17/05/24
n/a
n/a
FTSE All-Share
4,584.23
17:09 17/05/24
n/a
n/a
Pharmaceuticals & Biotechnology
23,313.10
16:49 17/05/24
-0.52%
-120.89
The company posted revenue of £7bn against expectations of £6.5bnm according to company-compiled estimates. Adjusted operating profit rose 8% to £2.1bn as GSK also maintained full-year guidance.
Its shingles vaccine, Shingrix, generated sales of £833m, beating estimates of £829m.
Reporting by Frank Prenesti for Sharecast.com